{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:56:00Z","timestamp":1768002960337,"version":"3.49.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>REP is an active combination in MM patients refractory to lenalidomide. REP is an all-oral and generally well-tolerated regimen.<\/jats:p>","DOI":"10.1182\/blood-2016-07-729236","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T02:29:36Z","timestamp":1474338576000},"page":"2297-2306","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma"],"prefix":"10.1182","volume":"128","author":[{"given":"Inger S.","family":"Nijhof","sequence":"first","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"},{"name":"Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens E.","family":"Franssen","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"},{"name":"Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard M. J.","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia K.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry R.","family":"Koene","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Antonius Hospital, Nieuwegein, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries C.","family":"Bloem","sequence":"additional","affiliation":[{"name":"Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aart","family":"Beeker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Spaarne Hospital, Hoofddorp, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Faber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rode Kruis Hospital, Beverwijk, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"van der Spek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, HagaZiekenhuis, Den Haag, The Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier","family":"Raymakers","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick-Johan","family":"van Spronsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"van Velzen","sequence":"additional","affiliation":[{"name":"Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berris","family":"van Kessel","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuna","family":"Mutis","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk M.","family":"Lokhorst","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"6","key":"2019111903361116700_B1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00277-012-1445-y","article-title":"SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.","volume":"91","author":"Barosi","year":"2012","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111903361116700_B2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2019111903361116700_B3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012; 26(5):1153].","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"2019111903361116700_B4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14656566.2013.805746","article-title":"New developments in the management and treatment of newly diagnosed and relapsed\/refractory multiple myeloma patients.","volume":"14","author":"van de Donk","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2019111903361116700_B5","author":"Dimopoulos"},{"issue":"7","key":"2019111903361116700_B6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111903361116700_B7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111903361116700_B8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMc1501348","article-title":"Treatment of relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111903361116700_B9","first-page":"253","article-title":"Lenalidomide for the treatment of relapsed and refractory multiple myeloma.","volume":"4","author":"van de Donk","year":"2012","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2019111903361116700_B10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111903361116700_B11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111903361116700_B12","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111903361116700_B13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2019111903361116700_B14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol Ther"},{"issue":"3","key":"2019111903361116700_B15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2019111903361116700_B16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"issue":"5","key":"2019111903361116700_B17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2019111903361116700_B18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111903361116700_B19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy.","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"2019111903361116700_B20","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res"},{"issue":"8","key":"2019111903361116700_B21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions.","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2019111903361116700_B22","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"2019111903361116700_B23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2141.2009.07931.x","article-title":"Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide\/dexamethasone-refractory myeloma.","volume":"148","author":"van de Donk","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111903361116700_B24","author":"Cancer Therapy Evaluation Program"},{"issue":"9","key":"2019111903361116700_B25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111903361116700_B26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903361116700_B27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2019111903361116700_B28","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111903361116700_B29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111903361116700_B30","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study.","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903361116700_B31","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"2019111903361116700_B32","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111903361116700_B33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903361116700_B34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111903361116700_B35","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903361116700_B36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111903361116700_B37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0300-2977(01)00140-1","article-title":"Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.","volume":"59","author":"de Weerdt","year":"2001","journal-title":"Neth J Med"},{"key":"2019111903361116700_B38","doi-asserted-by":"crossref","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","author":"H\u00e1jek","DOI":"10.1038\/leu.2016.176"},{"issue":"8","key":"2019111903361116700_B39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.22053","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111903361116700_B40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903361116700_B41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.13100","article-title":"Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.","volume":"168","author":"Reece","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111903361116700_B42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study.","volume":"150","author":"Schey","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111903361116700_B43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1179\/0001551214Z.00000000030","article-title":"Treatment with lenalidomide (Revlimid\u00ae), cyclophosphamide (Endoxan\u00ae) and prednisone (REP) in relapsed\/refractory multiple myeloma patients: results of a single centre retrospective study.","volume":"69","author":"Zelis","year":"2014","journal-title":"Acta Clin Belg"},{"issue":"21","key":"2019111903361116700_B44","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111903361116700_B45","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"2019111903361116700_B46","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"2019111903361116700_B47","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111903361116700_B48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.304.304","article-title":"Pomalidomide, bortezomib and dexamethason (PVD) for patients with relapsed lenalidomide refratory multiple myeloma (MM) [abstract].","volume":"124","author":"Lacy","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2019111903361116700_B49","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111903361116700_B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma [abstract].","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111903361116700_B51","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethason for relapsed\/refractory myltiple myeloma (RRMM): final efficacy and safety analysis [abstract].","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111903361116700_B52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.509.509","article-title":"A dose finding phase II trial of Isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed\/refractory multiple myeloma [abstract].","volume":"126","author":"Martin","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111903361116700_B53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/10428194.2012.719614","article-title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.","volume":"54","author":"Jimenez-Zepeda","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/19\/2297\/1396295\/2297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/19\/2297\/1396295\/2297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:36:29Z","timestamp":1574152589000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/19\/2297\/35505\/Phase-12-study-of-lenalidomide-combined-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":53,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-729236","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}